BioArctic & Eisai
3 shared events · Importance 4 · Last updated May 15, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
BioArctic is the original developer and licensor of the Alzheimer's drug Leqembi, receiving royalties from Eisai's global commercialization efforts.
Business
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab and is set to receive approximately SEK 880 million in royalties from the projected sales, indicating a positive financial outlook for the company.
Eisai: Eisai, BioArctic's partner, announced a projected revenue of JPY 143.5 billion for Lecanemab in FY 2026, demonstrating strong sales growth and continued commercialization efforts for the Alzheimer's drug.
May 15, 2026 · 6 articles
Regulatory
BioArctic: BioArctic, in collaboration with Eisai, developed Lecanemab. The extension of the PDUFA date for Lecanemab Iqlik's sBLA could delay potential revenue streams for BioArctic.
Eisai: Eisai is responsible for the clinical development, marketing authorization applications, and commercialization of Lecanemab. The FDA's extension of the PDUFA date for Lecanemab Iqlik's sBLA directly impacts Eisai's timeline for market expansion.
May 08, 2026 · 13 articles
Business
BioArctic: BioArctic is publishing its first quarter report for January - March 2026 and inviting investors, analysts, and media to a webcast and teleconference to present and comment on the report.
Eisai: Eisai is mentioned as a partner with BioArctic in the development of Leqembi.
May 13, 2026 · 7 articles
NEWSDESK
Explore this relationship live
Track how BioArctic and Eisai interact across events, view sentiment trends, and discover connected entities.
Open Dashboard